Concepts (116)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Depressive Disorder | 4 | 2013 | 53 | 0.870 |
Why?
|
| Restraint, Physical | 1 | 2022 | 12 | 0.820 |
Why?
|
| Psychiatry | 2 | 2016 | 27 | 0.800 |
Why?
|
| Inpatients | 1 | 2022 | 56 | 0.800 |
Why?
|
| Citalopram | 3 | 2007 | 7 | 0.720 |
Why?
|
| Hepatitis C | 4 | 2008 | 38 | 0.710 |
Why?
|
| Antidepressive Agents, Second-Generation | 3 | 2004 | 6 | 0.650 |
Why?
|
| Antidepressive Agents | 4 | 2018 | 29 | 0.630 |
Why?
|
| Referral and Consultation | 2 | 2008 | 87 | 0.540 |
Why?
|
| Physician Executives | 1 | 2016 | 5 | 0.530 |
Why?
|
| Delirium | 3 | 2006 | 13 | 0.500 |
Why?
|
| Interferon-alpha | 3 | 2007 | 50 | 0.480 |
Why?
|
| Endocrine System Diseases | 1 | 2013 | 5 | 0.450 |
Why?
|
| Hepatitis C, Chronic | 2 | 2007 | 30 | 0.420 |
Why?
|
| Serotonin Uptake Inhibitors | 2 | 2004 | 26 | 0.420 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2013 | 44 | 0.420 |
Why?
|
| Substance-Related Disorders | 2 | 2013 | 166 | 0.340 |
Why?
|
| Cardiovascular Diseases | 1 | 2013 | 346 | 0.340 |
Why?
|
| Antipsychotic Agents | 3 | 2006 | 24 | 0.320 |
Why?
|
| Mental Disorders | 2 | 2008 | 103 | 0.320 |
Why?
|
| Depressive Disorder, Major | 2 | 2002 | 125 | 0.310 |
Why?
|
| Gastroenterology | 1 | 2008 | 14 | 0.300 |
Why?
|
| Attitude of Health Personnel | 1 | 2008 | 139 | 0.280 |
Why?
|
| Finger Injuries | 1 | 2006 | 1 | 0.270 |
Why?
|
| Self Mutilation | 1 | 2006 | 1 | 0.270 |
Why?
|
| Antiviral Agents | 1 | 2007 | 104 | 0.270 |
Why?
|
| Humans | 17 | 2022 | 26856 | 0.260 |
Why?
|
| Comorbidity | 4 | 2013 | 251 | 0.260 |
Why?
|
| Hallucinations | 2 | 2004 | 4 | 0.260 |
Why?
|
| Spinal Cord Injuries | 1 | 2006 | 55 | 0.250 |
Why?
|
| Depression | 1 | 2007 | 210 | 0.240 |
Why?
|
| Adult | 8 | 2022 | 7389 | 0.230 |
Why?
|
| Histamine H1 Antagonists | 1 | 2004 | 1 | 0.230 |
Why?
|
| Promethazine | 1 | 2004 | 1 | 0.230 |
Why?
|
| Psychoses, Substance-Induced | 1 | 2004 | 2 | 0.230 |
Why?
|
| Indans | 1 | 2003 | 2 | 0.220 |
Why?
|
| Nootropic Agents | 1 | 2003 | 4 | 0.220 |
Why?
|
| Hip Fractures | 1 | 2003 | 10 | 0.220 |
Why?
|
| Male | 10 | 2018 | 12866 | 0.220 |
Why?
|
| Cyclohexanols | 1 | 2003 | 5 | 0.220 |
Why?
|
| Epilepsy, Tonic-Clonic | 1 | 2003 | 5 | 0.220 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2003 | 29 | 0.220 |
Why?
|
| Methylphenidate | 1 | 2003 | 7 | 0.220 |
Why?
|
| Haloperidol | 1 | 2003 | 8 | 0.220 |
Why?
|
| Female | 11 | 2018 | 14462 | 0.210 |
Why?
|
| Piperidines | 1 | 2003 | 42 | 0.210 |
Why?
|
| Central Nervous System Stimulants | 1 | 2003 | 30 | 0.210 |
Why?
|
| Hypnotics and Sedatives | 1 | 2003 | 29 | 0.210 |
Why?
|
| Influenza, Human | 1 | 2004 | 84 | 0.210 |
Why?
|
| Psychomotor Agitation | 1 | 2022 | 7 | 0.210 |
Why?
|
| Clinical Protocols | 1 | 2022 | 45 | 0.200 |
Why?
|
| Patient Safety | 1 | 2022 | 36 | 0.200 |
Why?
|
| Pyridines | 1 | 2003 | 99 | 0.200 |
Why?
|
| Tuberculosis, Central Nervous System | 1 | 2002 | 1 | 0.200 |
Why?
|
| Pirenzepine | 1 | 2002 | 8 | 0.200 |
Why?
|
| Psychotic Disorders | 1 | 2002 | 17 | 0.200 |
Why?
|
| Drug Therapy, Combination | 4 | 2018 | 203 | 0.190 |
Why?
|
| Reproducibility of Results | 1 | 2022 | 748 | 0.170 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2018 | 588 | 0.170 |
Why?
|
| Postoperative Complications | 1 | 2003 | 605 | 0.160 |
Why?
|
| Severity of Illness Index | 3 | 2007 | 447 | 0.150 |
Why?
|
| Minocycline | 1 | 2018 | 7 | 0.150 |
Why?
|
| Bipolar Disorder | 1 | 2018 | 39 | 0.150 |
Why?
|
| Aspirin | 1 | 2018 | 119 | 0.140 |
Why?
|
| Treatment Outcome | 4 | 2018 | 2267 | 0.140 |
Why?
|
| Aged | 4 | 2013 | 5169 | 0.130 |
Why?
|
| Demography | 1 | 2016 | 91 | 0.130 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 73 | 0.130 |
Why?
|
| Faculty, Medical | 1 | 2016 | 51 | 0.130 |
Why?
|
| Patient Care Team | 2 | 2008 | 62 | 0.110 |
Why?
|
| Gastrointestinal Diseases | 1 | 2013 | 54 | 0.110 |
Why?
|
| Geriatric Assessment | 1 | 2013 | 86 | 0.110 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2013 | 62 | 0.110 |
Why?
|
| Middle Aged | 4 | 2018 | 6825 | 0.100 |
Why?
|
| Quality of Life | 2 | 2007 | 463 | 0.090 |
Why?
|
| United States | 1 | 2016 | 2035 | 0.090 |
Why?
|
| Hospitals, University | 1 | 2008 | 26 | 0.080 |
Why?
|
| Adolescent | 2 | 2007 | 2960 | 0.080 |
Why?
|
| Health Services Needs and Demand | 1 | 2008 | 36 | 0.080 |
Why?
|
| Data Collection | 1 | 2008 | 101 | 0.070 |
Why?
|
| Ribavirin | 1 | 2007 | 9 | 0.070 |
Why?
|
| Health Services Accessibility | 1 | 2008 | 91 | 0.070 |
Why?
|
| Secondary Prevention | 1 | 2007 | 45 | 0.070 |
Why?
|
| Mass Screening | 1 | 2008 | 141 | 0.070 |
Why?
|
| Quadriplegia | 1 | 2006 | 4 | 0.070 |
Why?
|
| Thiazoles | 1 | 2006 | 50 | 0.060 |
Why?
|
| Piperazines | 1 | 2006 | 45 | 0.060 |
Why?
|
| Pilot Projects | 1 | 2007 | 391 | 0.060 |
Why?
|
| Risk Factors | 2 | 2003 | 2017 | 0.060 |
Why?
|
| Cervical Vertebrae | 1 | 2006 | 112 | 0.060 |
Why?
|
| Oklahoma | 1 | 2008 | 971 | 0.060 |
Why?
|
| Follow-Up Studies | 1 | 2007 | 981 | 0.060 |
Why?
|
| Mental Status Schedule | 1 | 2003 | 9 | 0.060 |
Why?
|
| Venlafaxine Hydrochloride | 1 | 2003 | 1 | 0.050 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2003 | 27 | 0.050 |
Why?
|
| Anxiety Disorders | 1 | 2003 | 58 | 0.050 |
Why?
|
| Liver Function Tests | 1 | 2002 | 9 | 0.050 |
Why?
|
| Aspartate Aminotransferases | 1 | 2002 | 20 | 0.050 |
Why?
|
| Alanine Transaminase | 1 | 2002 | 25 | 0.050 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2002 | 18 | 0.050 |
Why?
|
| Treatment Refusal | 1 | 2002 | 8 | 0.050 |
Why?
|
| Benzodiazepines | 1 | 2002 | 10 | 0.050 |
Why?
|
| Length of Stay | 1 | 2003 | 218 | 0.050 |
Why?
|
| Epilepsy | 1 | 2002 | 32 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2003 | 368 | 0.050 |
Why?
|
| Oxandrolone | 1 | 2000 | 1 | 0.040 |
Why?
|
| Anabolic Agents | 1 | 2000 | 10 | 0.040 |
Why?
|
| Injections, Intramuscular | 1 | 1999 | 21 | 0.040 |
Why?
|
| Burns | 1 | 2000 | 16 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 1999 | 218 | 0.040 |
Why?
|
| Sick Role | 1 | 1998 | 9 | 0.040 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2018 | 93 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2018 | 93 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2018 | 399 | 0.030 |
Why?
|
| Logistic Models | 1 | 2018 | 397 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2018 | 190 | 0.030 |
Why?
|